<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23629759</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Novel substituted heteroaromatic piperazine and piperidine derivatives as inhibitors of human enterovirus 71 and coxsackievirus a16.</ArticleTitle><Pagination><StartPage>5059</StartPage><EndPage>5071</EndPage><MedlinePgn>5059-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules18055059</ELocationID><Abstract><AbstractText>A series of substituted heteroaromatic piperazine and piperidine derivatives were found through virtual screening based on the structure of human enterovirus 71 capsid protein VP1. The preliminary biological evaluation revealed that compounds 8e and 9e have potent activity against EV71 and Coxsackievirus A16 with low cytotoxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery of the Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, Liangning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongliang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhuan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Ruiyuan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Wu</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zhibing</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Junhai</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="Y">Piperazines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="Y">Piperidines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23629759</ArticleId><ArticleId IdType="pmc">PMC6269887</ArticleId><ArticleId IdType="doi">10.3390/molecules18055059</ArticleId><ArticleId IdType="pii">molecules18055059</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Racaniello V.R. In: Fields Virology. 5th. Knipe D.M., Howley P.M., editors. Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2007. pp. 796&#x2013;839.</Citation></Reference><Reference><Citation>Bruu A.L. A Practical Guide to Clinical Virology. John Wiley &amp; Sons, Ltd.; Chichester, UK: 2003. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses and newer Enteroviruses; pp. 44&#x2013;45.</Citation></Reference><Reference><Citation>Blomberg J., Lycke E. New enterovirus type associated with epidemic of aseptic meningitis and/orhand, and mouth disease. Lancet. 1974;304:112. doi: 10.1016/S0140-6736(74)91684-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)91684-5</ArticleId><ArticleId IdType="pubmed">4136956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Lin T.Y. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354:1682&#x2013;1686. doi: 10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum L.C.S., Wong K.T. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet. 1998;352:1391.</Citation><ArticleIdList><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., He Y.X. Pathology of enterovirus 71 infection: An autopsy study of 5 cases. Zhonghua Bing Li Xue Za Zhi. 2009;38:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern J.H., Lee C.C. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg. Med. Chem. Lett. 2004;14:5051&#x2013;5056. doi: 10.1016/j.bmcl.2004.07.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2004.07.084</ArticleId><ArticleId IdType="pubmed">15380197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.J., Shie J.J. Design, Synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorgan. Med. Chem. 2008;16:7388&#x2013;7398. doi: 10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Li W. Research progress of enterovirus 71 vaccine. Prog. Microbiol. Immunol. 2012;40:89&#x2013;94.</Citation></Reference><Reference><Citation>Shia K.S., Li W.T. Design, Synthesis, and Structure&#x2212;Activity Relationship of Pyridyl Imidazolidinones: A Novel Class of Potent and Selective Human Enterovirus 71 Inhibitors. J. Med. Chem. 2002;45:1644&#x2013;1655. doi: 10.1021/jm010536a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rei L.K., Shin R.S. Strategies to develop antivirals against enterovirus 71. J. Virol. 2013;10:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung J.H., Yi R.J. Traditional Chinese medicine application in HIV: An in silico study. J. Biomol. Struct. Dyn. 2012:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23252879</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S.C., Hung J.H. Two Birds with One Stone? Possible Dual-Targeting H1N1 Inhibitors from Traditional Chinese Medicine. PLoS Comput. Biol. 2011;7:e1002315. doi: 10.1371/journal.pcbi.1002315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002315</ArticleId><ArticleId IdType="pmc">PMC3245300</ArticleId><ArticleId IdType="pubmed">22215997</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., Arnold E. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Filman D.J., Syed R. Structual factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO. 1989;8:1567&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400988</ArticleId><ArticleId IdType="pubmed">2548847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S.Y., Zheng Z.B. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors. Bioorgan. Med. Chem. 2009;17:621&#x2013;624. doi: 10.1016/j.bmc.2008.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.11.061</ArticleId><ArticleId IdType="pubmed">19091578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Xiao J. Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors. Bioorg. Med. Chem. Lett. 2011;21:1057&#x2013;1059. doi: 10.1016/j.bmcl.2010.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2010.12.001</ArticleId><ArticleId IdType="pubmed">21215622</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D.L., Hubbard V.D. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: Novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 2004;48:1766&#x2013;1772. doi: 10.1128/AAC.48.5.1766-1772.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X.-Y., Wang H.-Q. Synthesis and antiviral activity of N-Phenylbenzamide derivatives, a novel class of Enterovirus 71 inhibitors. Molecules. 2013;18:3630&#x2013;3640. doi: 10.3390/molecules18033630.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules18033630</ArticleId><ArticleId IdType="pmc">PMC6270001</ArticleId><ArticleId IdType="pubmed">23519203</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng E.C., Shoiche B.K. Automated docking with grid-based energy evaluation. J. Comput. Chem. 1992;13:505&#x2013;524. doi: 10.1002/jcc.540130412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.540130412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiung G.D., Fong C. Picornaviridae. In: Hsiung G.D., Fong C.K.Y., Landry M.L., editors. Hsiung&#x2019;s Diagnostic Virology. Yale University Press; New Haven, CT, USA: 1994. pp. 119&#x2013;140.</Citation></Reference><Reference><Citation>Nakayama M., Suzuki K. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 1993;21:289&#x2013;299. doi: 10.1016/0166-3542(93)90008-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(93)90008-7</ArticleId><ArticleId IdType="pubmed">8215301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>